Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase I-II Trial, Multicenter, Open, Exploring Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients (TRASTS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02275286
Recruitment Status : Unknown
Verified February 2017 by Grupo Espanol de Investigacion en Sarcomas.
Recruitment status was:  Recruiting
First Posted : October 27, 2014
Last Update Posted : February 23, 2017
Sponsor:
Collaborators:
Centre Leon Berard
Italian Sarcoma Group
Information provided by (Responsible Party):
Grupo Espanol de Investigacion en Sarcomas

Brief Summary:

Phase I-II trial that combines trabectedin plus radiotherapy for tumor reduction response measure in two cohorts of patients:

Cohort A: Patients with diagnosis of non-operable or unresectable or not oncologically recommended metastasectomy of limited to lung metastases soft tissue sarcoma.

Cohort B: Patients with locally advanced resectable Myxoid Liposarcoma. Phase I: escalating dose of 1.3 or 1.5 mg/m2. Radiotherapy for cohort A: 30Gy in 10 fractions (3Gy/fraction) Radiotherapy for cohort B: 45Gy in 25 fractions (1.8Gy/fraction) A translational substudy is developed to analyse different biomarkers predictive value.


Condition or disease Intervention/treatment Phase
Liposarcoma, Myxoid Sarcoma, Soft Tissue Drug: Trabectedin Radiation: Radiotherapy Phase 1 Phase 2

Detailed Description:

In this study investigators plan to measure tumor response (RECIST and Choi criteria) when administering trabectedin standard dose or inferior with simultaneous radiotherapy treatment. The hypothesis states that administering trabectedin at 1.3mg/m2 or ≤1.5mg/m2 plus Radiotherapy 30-45Gy shows synergic activity that turns into tumor shrinkage.

A phase I trial (dose escalation level of 1.3 or 1.5 mg/m2) will provide the proper dose level to perform a phase II trial to measure RECIST and Choi response, progression free survival, overall survival and register safety and quality of life details.

To cohorts are indicated for this trial, A: Patients with diagnosis of non-operable or unresectable or not oncologically recommended metastasectomy of limited to lung metastases soft tissue sarcoma and cohort B: Patients with locally advanced resectable Myxoid Liposarcoma. Unlimited cycles of chemotherapy are considered to be beneficial for cohort A patients, whereas cohort B only 3 cycles are indicated. About radiotherapy treatment, 30Gy will be given to cohort A patients, whereas cohort B will receive 45Gy. TCs and MRI are selected for imaging purposes.

Several biomarkers are selected to perform FFPE tumor assays in relation to prediction


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 96 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I-II Prospective Trial, Multicenter, Open Label, Exploring the Combination of Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients
Study Start Date : November 2014
Estimated Primary Completion Date : December 2017
Estimated Study Completion Date : June 2018

Resource links provided by the National Library of Medicine

Drug Information available for: Trabectedin

Arm Intervention/treatment
Experimental: Trabectedin+Radiotherapy
Trabectedin 1.3 or 1.5mg/m2 and radiotherapy 30Gy or 45Gy.
Drug: Trabectedin
Escalating dose of 1.3 or 1.5mg/m2, i.v 24h, once every 3 weeks. Cohort A: unlimited cycles Cohort B: 3 cycles
Other Name: Yondelis

Radiation: Radiotherapy
3D conformal radiotherapy (3D-CRT) or intensity modulated radiotherapy (IMRT) providing: Cohort A: 30Gy in 10 fractions (3Gy/fraction) Cohort B: 45Gy in 25 fractions (1.8Gy/fraction)




Primary Outcome Measures :
  1. Tumor size [ Time Frame: every 6 weeks for 24 months ]
    Image tumor assessment measured by RECIST criteria.


Secondary Outcome Measures :
  1. Number and type of adverse events [ Time Frame: every 21 days until 30 days after last dose or during 25 months ]
    CTCAE v4.03 adverse events registration to evaluate safety

  2. Number of months without progression [ Time Frame: 24 months ]
    Progression free survival (PFS)

  3. Number of months alive [ Time Frame: 24 months ]
    Overall survival (OS)

  4. Tumor size [ Time Frame: every 6 weeks during 24 months ]
    Image tumor assessment measured by Choi criteria.

  5. Questionnaire [ Time Frame: every 3 months during 24 months ]
    QLQ-C30 EORTC questionnaire to evaluate patient quality of life



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Cohort A: STS

Inclusion Criteria:

  1. The patient must sign voluntarily the informed consent form before any study test is conducted that is not part of routine patient care.
  2. Aged between 18 and 70.
  3. Patients must have a diagnostic of Soft Tissue Sarcoma with metastasis limited to lung, and not suitable for metastasectomy or surgery resection or not oncologically recommended metastasectomy
  4. Patients must have documentation of disease progression within 6 months prior to study entry.
  5. The patient must have been considered eligible for systemic chemotherapy. A maximum of two previous lines for advanced/metastatic disease are allowed as long as trabectedin has not been included.
  6. The following histological subtypes can be included:

    • Undifferentiated pleomorphic sarcoma (previously, malignant fibrous histiocytoma)
    • Leiomyosarcoma
    • Angiosarcoma/ epithelial hemangioendothelioma
    • Liposarcoma and its variants (well differentiated, dedifferentiated, myxoid/round cells, pleomorphic)
    • Synovial sarcoma
    • Fibrosarcoma and its variants (epithelial fibrosarcoma/low grade fibromyxoid sarcoma)
    • Hemangiopericytoma/solitary fibroid tumor
    • Neurogenic sarcoma (Malignant peripheral nerve sheath tumor, MPNST)
    • Myxofibrosarcoma
    • Epithelioid Sarcoma
    • Unclassified sarcoma (spindle cell/epithelioid/pleomorphic/myxoid)
  7. Measurable disease, according to RECIST V 1.1 criteria
  8. Performance status ≤1 (ECOG).
  9. Adequate respiratory functions: FEV1 >1L
  10. Adequate bone marrow function (hemoglobin > 10 g/dl, leukocytes ≥ 3.000/mm3, neutrophils ≥ 1.500/mm3, platelets ≥ 100.000/mm3). Patients with plasma creatinine ≤ 1,6 mg/dl, transaminases ≤ 2.5 times the UNL, total bilirubin ≤ UNL, CPK ≤ 2.5 times UNL, alkaline phosphatase ≤ 2.5 times the UNL are acceptable. If the increase of alkaline phosphatase is > 2.5 times the UNL, then the alkaline phosphatase liver fraction and/or 5' nucleotidase and/or GGT must be ≤ UNL.
  11. Men or women of child bearing potential should be using an effective method of contraception before entry into the study and throughout the same and for 6 months after ending the study. Women of childbearing potential must have a negative urine pregnancy test before study entry.
  12. Normal cardiac function with a LVEF ≥ 50% by echocardiogram or MUGA.
  13. Disease distribution in lungs allows meeting with normal tissue constraints of radiation therapy. Radiation oncologist must confirm this point.
  14. It should be performed HBV and HCV serologies prior to inclusion. If HbsAg is positive it is recommended to reject the existence of replicative phase (HbaAg+, DNA VHB+). If these were positives the inclusion is not recommended, remaining at investigators' discretion the preventive treatment with lamivudine. If a potential patient is positive for anti-HCV antibodies, presence of the virus should be ruled out with a qualitative PCR, or the patient should NOT be included in the study (if a qualitative PCR cannot be performed then patient will not be able to enter the study)
  15. Patient must have a Central Venous Catheter for treatment

Exclusion Criteria:

  1. Previous treatment with trabectedin or radiotherapy involving any lung field.
  2. Performance status ≥ 2 (ECOG).
  3. Metastases out of those located in lungs.
  4. Plasma bilirubin > UNL.
  5. Creatinine > 1.6 mg/dL.
  6. History of other neoplastic disease with the exception of basal cell carcinoma or in situ cervical cancer adequately treated.
  7. Severe COPD or other severe pulmonary diseases.
  8. Significant cardiovascular disease (for example, dyspnea > 2 NYHA)
  9. Significant systemic diseases grade 3 or higher on the NCI-CTCAE v4.03 scale, that limit patient availability, or according to investigator judgment may contribute significantly to treatment toxicity.
  10. Uncontrolled bacterial, mycotic or viral infections.
  11. Known positive test for infection by human immunodeficiency virus (HIV).
  12. Women who are pregnant or breast-feeding.
  13. Psychological, familial, social or geographic circumstances that limit the patient's ability to comply with the protocol or informed consent.
  14. Patients participating in another clinical trial or receiving any other investigational product.
  15. Patients who had participated in another clinical trial and/or had received any other investigational product in the last 30 days prior to inclusion.
  16. Histologies other than those described in inclusion criteria.

Cohort B: ML

Inclusion criteria:

  1. The patient must sign voluntarily the informed consent form before any study test is conducted that is not part of routine patient care.
  2. Aged between 18 and 70.
  3. Pathological diagnosis of Myxoid Liposarcoma, deep located and more than 5 cm or superficial more than 10 cm.
  4. Tumor must be resectable and without evidence of regional or distal spread after adequate staging procedure. Tumor must be located in limbs or superficial trunk wall.
  5. Disease distribution allows meeting with normal tissue constraints of radiation therapy. Radiation oncologist must confirm this point.
  6. Measurable disease, according to RECIST V 1.1 criteria
  7. Performance status 0-1 (ECOG).
  8. Adequate bone marrow function (hemoglobin > 10 g/dL, leukocytes ≥ 3.000/mm3, neutrophils ≥ 1.500/mm3, platelets ≥ 100.000/mm3). Patients with plasma creatinine ≤ 1,6 mg/dL, transaminases ≤ 2.5 times the UNL, total bilirubin ≤ UNL, CPK ≤ 2.5 times UNL, alkaline phosphatase ≤ 2.5 times the UNL are acceptable. If the increase of alkaline phosphatase is > 2.5 times the UNL, then the alkaline phosphatase liver fraction and/or 5' nucleotidase and/or GGT must be ≤ UNL.
  9. Men or women of child bearing potential should be using an effective method of contraception before entry into the study and throughout the same and for 6 months after ending the study. Women of childbearing potential must have a negative urine pregnancy test before study entry.
  10. Normal cardiac function with a LVEF ≥ 50% by echocardiogram or MUGA.
  11. It should be performed HBV and HCV serologies prior to inclusion. If HbsAg is positive it is recommended to reject the existence of replicative phase (HbaAg+, DNA HBV+). If these were positives the inclusion is not recommended, remaining at investigators' discretion the preventive treatment with lamivudine. If a potential patient is positive for anti-HCV antibodies, presence of the virus should be ruled out with a qualitative PCR, or the patient should NOT be included in the study (if a qualitative PCR cannot be performed then patient will not be able to enter the study).
  12. Patient may have had one previous chemotherapy line.
  13. Patient must have a Central Venous Catheter for treatment.

Exclusion criteria:

  1. More than one previous chemotherapy treatment for local disease including trabectedin.
  2. Radiotherapy involving the tumoral bed.
  3. Performance status ≥ 2 (ECOG).
  4. Presence of metastases or lymph node involvement by the tumor.
  5. Location other than limb or superficial trunk wall.
  6. Plasma bilirubin > UNL.
  7. Creatinine > 1.6 mg/dL.
  8. History of other neoplastic disease with the exception of basal cell carcinoma or in situ cervical cancer adequately treated.
  9. Significant cardiovascular disease (for example, dyspnea > 2 NYHA)
  10. Significant systemic diseases grade 3 or higher on the NCI-CTCAE v4.03 scale, that limit patient availability, or according to investigator judgment may contribute significantly to treatment toxicity.
  11. Uncontrolled bacterial, mycotic or viral infections.
  12. Known positive test for infection by human immunodeficiency virus (HIV).
  13. Women who are pregnant or breast-feeding.
  14. Psychological, familial, social or geographic circumstances that limit the patient's ability to comply with the protocol or informed consent.
  15. Patients participating in another clinical trial or receiving any other investigational product.
  16. Patients who had participated in another clinical trial and/or had received any other investigational product in the last 30 days prior to inclusion.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02275286


Contacts
Layout table for location contacts
Contact: Melissa Fernandez-Pinto, MSc 0034912866807 melissa.crc@grupogeis.org
Contact: Mamen Roncero-DeJuan, RGN 0034912866807 mamen@grupogeis.org

Locations
Layout table for location information
France
Institut Bergonié Recruiting
Bordeaux, France, 33000
Contact: Antoine Italiano, MD         
Centre Oscar Lambret Not yet recruiting
Lille, France, 59000
Contact: Nicolas Penel, MD         
Centre Léon Berard Recruiting
Lyon, France
Principal Investigator: Jean Yves Blay, MD         
Italy
Istituto Clinico Humanitas Not yet recruiting
Rozzano, Milan, Italy, 20089
Contact: Armando Santoro, MD         
Centro di Referimento Ocologico Not yet recruiting
Aviano, Italy, 33081
Contact: Angela Buonadonna, MD         
Istituto Ortopedico Rizzoli Not yet recruiting
Bologna, Italy, 40136
Contact: Stefano Ferrari , MD         
Istituto Oncologico Recruiting
Candiolo, Italy, 10060
Contact: Giovanni Grignani, MD         
Istituto Nazionale dei Tumori Recruiting
Milan, Italy, 20133
Contact: Alessandro Gronchi, MD       alessandro.gronchi@istitutotumori.mi.it   
Spain
Hospital Miguel Servet Recruiting
Zaragoza, Aragón, Spain, 50009
Contact: Javier Martínez-Trufero, MD         
Hospital Sant Pau Recruiting
Barcelona, Cataluña, Spain, 08041
Contact: Antonio Lopez-Posa, MD         
Hospital Son Espases Recruiting
Palma de Mallorca, Mallorca, Spain, 07010
Contact: Pablo Luna, MD         
Hospital Universitario Canarias Recruiting
San Cristobal de la Laguna, Tenerife, Spain, 38320
Contact: Josefina Cruz, MD         
Hospital Vall d'Hebrón Recruiting
Barcelona, Spain, 08035
Contact: Claudia Valverde, MD         
Hospital Puerta de Hierro Recruiting
Madrid, Spain, 28006
Contact: Ricardo Cubedo, MD         
Hospital Universitario Gregorio Marañón Recruiting
Madrid, Spain, 28007
Contact: Rosa Álvarez, MD         
Hospital Uniersitario La Paz Recruiting
Madrid, Spain, 28046
Contact: Andres Redondo, MD         
Hospital Virgen del Rocío Recruiting
Sevilla, Spain, 41013
Contact: Javier Martín-Broto, MD       javier.martin@ssib.es   
Sponsors and Collaborators
Grupo Espanol de Investigacion en Sarcomas
Centre Leon Berard
Italian Sarcoma Group
Investigators
Layout table for investigator information
Principal Investigator: Javier Martín-Broto, MD Hospital Virgen del Rocío

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Grupo Espanol de Investigacion en Sarcomas
ClinicalTrials.gov Identifier: NCT02275286     History of Changes
Other Study ID Numbers: GEIS 37
First Posted: October 27, 2014    Key Record Dates
Last Update Posted: February 23, 2017
Last Verified: February 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Grupo Espanol de Investigacion en Sarcomas:
sarcoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Sarcoma
Liposarcoma
Liposarcoma, Myxoid
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Adipose Tissue
Trabectedin
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents